Myelo 00Y
Alternative Names: Myelo-00YLatest Information Update: 24 Sep 2024
At a glance
- Originator Myelo Therapeutics
- Class Radioprotectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute radiation syndrome
Most Recent Events
- 30 Jun 2023 Preclinical trials in Acute radiation syndrome in Germany (unspecified route), prior to June 2023 (Myelo Therapeutics pipeline, June 2023)